舌下神经刺激治疗唐氏综合征青少年阻塞性睡眠呼吸暂停
该病例系列纳入6例12-18岁唐氏综合征合并腺扁桃体切除术后持续重度OSA的青少年,植入Inspire舌下神经刺激器。随访6-12个月,治疗耐受良好,AHI降低56%-85%,4例AHI<5次/h、2例<10次/h,OSA-18生活质量评分显著改善。
要点
- 舌下神经刺激在唐氏综合征青少年中耐受良好且有效。
- 随访6-12个月AHI降低56%-85%,多数患儿AHI降至<10次/h。
- OSA-18生活质量评分出现临床显著改善。
核心结论
- 舌下神经刺激在研究人群中耐受良好且有效,可能成为腺扁桃体切除术后难治性OSA且无法耐受正压通气患者的治疗选择。
研究设计与样本
- 病例系列,纳入首批6例接受舌下神经刺激器植入的唐氏综合征青少年。
- 参与者为6例12-18岁唐氏综合征患者,均有腺扁桃体切除术后重度OSA(AHI>10次/h)。
- 干预为Inspire舌下神经刺激器植入。
主要发现
- 6例患者(4男2女,12-18岁)治疗耐受良好,平均使用5.6-10.0小时/晚。
- 随访6-12个月,AHI降低56%-85%,4例AHI<5次/h,2例<10次/h。
- OSA-18总体变化评分均值(SD)为1.5(0.6),范围0.9-2.3。
关键数值与推荐
- 纳入标准为唐氏综合征、12-18岁、腺扁桃体切除术后AHI>10次/h的重度OSA。
- 疗效评价指标为AHI和OSA-18生活质量量表评分。
- 依从性以设备记录的使用小时数衡量。
临床怎么用
- 对腺扁桃体切除术后持续重度OSA且无法耐受正压通气的唐氏综合征青少年,可考虑舌下神经刺激。
- 需监测不良事件并通过设备记录评估治疗依从性。
- 疗效评估应结合AHI和OSA-18生活质量评分。
局限性
- 为病例系列,样本量仅6例,证据级别有限。
- 随访时间6-12个月,缺乏长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Obstructive sleep apnea (OSA) affects up to 60% of children with Down syndrome (DS) and may persist in half of patients after adenotonsillectomy. Children with DS who have persistent OSA often do not tolerate treatment with positive pressure airway support devices or tracheotomy for their residual moderate to severe OSA. The hypoglossal nerve stimulator is an implantable device that delivers an electrical impulse to anterior branches of the hypoglossal nerve in response to respiratory variation, resulting in tongue base protrusion that alleviates upper airway obstruction in adults. OBJECTIVE: To determine whether hypoglossal nerve stimulation is safe and effective in children with DS. DESIGN, SETTING, AND PARTICIPANTS: Case series of the first 6 adolescents with DS to undergo hypoglossal nerve stimulator implantation. Participants were 6 children and adolescents (12-18 years) with DS and severe OSA (apnea hypopnea index [AHI] > 10 events/h) despite prior adenotonsillectomy. INTERVENTION: Inspire hypoglossal nerve stimulator placement. MAIN OUTCOMES AND MEASURES: Patients were monitored for adverse events. Adherence to therapy was measured by hours of use recorded by the device. Efficacy was evaluated by comparing AHI and OSA-18, a validated quality-of-life instrument, scores at baseline and follow-up. RESULTS: In 6 patients (4 male, 2 female; aged 12-18 years), hypoglossal nerve stimulator therapy was well tolerated (mean use, 5.6-10.0 h/night) and effective, resulting in significant improvement in OSA. At 6- to 12-month follow-up, patients demonstrated a 56% to 85% reduction in AHI, with an overall AHI of less than 5 events/h in 4 children and less than 10 events/h in 2 children. Children also demonstrated a clinically significant improvement (mean [SD] overall change score, 1.5 [0.6]; range, 0.9-2.3) on the OSA-18, a validated quality-of-life instrument. CONCLUSIONS AND RELEVANCE: Hypoglossal nerve stimulation was well tolerated and effective in the study population, representing a potential therapeutic option for patients with DS and refractory OSA after adenotonsillectomy who are unable to tolerate positive pressure airway devices. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT2344108.
引用
- Diercks GR, Wentland C, Keamy D, et al. Hypoglossal Nerve Stimulation in Adolescents With Down Syndrome and Obstructive Sleep Apnea. JAMA Otolaryngol Head Neck Surg. 2018. PMID: 29098288. doi:10.1001/jamaoto.2017.1871
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。